Aiforia - Medical Image Analysis Software

@Antti_Siltanen made his diagnosis: tough luck for investors :slight_smile: : Aiforia: Diagnoosimme on kasvun puutos - Inderes

Aiforia issued a profit warning on Tuesday, stating that its revenue for January–June 2026 remained weak. According to the company, the poor performance relative to our forecasts and the company’s internal expectations was due to delays in pending customer contracts and the fact that revenue recognition from contracts signed early in the year is weighted towards H2. The customer wins of recent years appear to be turning into recurring revenue frustratingly slowly, and the growth we expected is being pushed further into the future. We are significantly lowering our revenue forecasts for the coming years and cutting our target price to 1.30 euros (previously 2.40 €). We are downgrading our recommendation to “Reduce” (previously “Add”) based on the lowered forecasts. In our view, the long-term potential is still there. However, the uncertainty surrounding its realization has increased significantly, which in our view justifies a more cautious recommendation than before.

12 Likes